CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended June 30, 2016.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “The second quarter was one marked by continued advancements and outreach. In the INSPIRE study, a fourth patient converted from a complete to an incomplete spinal cord injury, putting us one step closer to achieving the Objective Performance Criterion.
Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “The second quarter was one marked by continued advancements and outreach. In the INSPIRE study, a fourth patient converted from a complete to an incomplete spinal cord injury, putting us one step closer to achieving the Objective Performance Criterion.
